Solid Biosciences Inc. Exchange Fees
Solid Biosciences Inc. (SLDB) reported Exchange Fees of $517.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ExchangeFees · last filed 2023-05-11
- Solid Biosciences Inc. exchange fees for the quarter ending 2023-03-31 was $517.00K, a 120.00% increase year-over-year.
- Solid Biosciences Inc. exchange fees for the quarter ending 2022-03-31 was $235.00K.
- Solid Biosciences Inc. exchange fees for the quarter ending 2021-09-30 was $194.00K.
- Solid Biosciences Inc. exchange fees for the quarter ending 2020-09-30 was $0.00.
- Solid Biosciences Inc. exchange fees for fiscal 2022 was $1.97M.
| Period end | Exchange Fees 1 month | Exchange Fees 1 month as first filed | Exchange Fees 3 month | Exchange Fees 9 month | Exchange Fees 12 month |
|---|---|---|---|---|---|
| 2023-03-31 | $517.00K 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | $1.97M 10-K · filed 2023-03-23 | ||||
| 2022-03-31 | $235.00K 10-Q · filed 2023-05-11 | ||||
| 2021-09-30 | $194.00K 10-Q · filed 2021-11-03 | $381.00K 10-Q · filed 2021-11-03 | |||
| 2020-11-30 | $700.00K 10-K · filed 2022-03-14 | $200.00K 10-Q · filed 2021-05-14 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |